Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tomudex · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tomudex | DRUG | - |
| Radiotherapy | PROCEDURE | - |
| Haematology | PROCEDURE | - |
| Biochemistry | PROCEDURE | - |
Inclusion Criteria: * Confirmed diagnosis of inoperable/recurrent rectal cancer * Age \> 18 years * At least 1 measurable lesion should be present * WHO performance score \< 2 * Life expentancy of at least 12 weeks * Subjects will be considered appropriate to receive systemic chemotherapy and pelvi...
Tomudex is a small molecule oncology drug being studied for the treatment of inoperable or recurrent rectal cancer. It is administered in combination with radiotherapy, as evaluated in a Phase 2 clinical trial. The drug is intended for patients with this specific advanced form of rectal cancer.
Tomudex is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is responsible for the clinical development of Tomudex for the treatment of inoperable or recurrent rectal cancer.
Tomudex is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 2 trial for Tomudex in inoperable or recurrent rectal cancer has been completed, with 49 patients enrolled.
Tomudex has one completed clinical trial, identified as NCT00590278, titled "A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer." This Phase 2 trial enrolled 49 patients in Turkey and included adults aged 18 years and older.
Tomudex is a small molecule drug used in oncology. Its specific molecular target is not disclosed in the available information, so its mechanism of action is not detailed here. It is being studied in combination with radiotherapy for the treatment of inoperable or recurrent rectal cancer.